{"title": "Conventional Therapeutic Drugs and Traditional Herbal Medicine in Prevention and Treatment of Novel Corona Virus (COVID-19): An Update", "author": "Ramakant Yadav; Yogesh Chand Yadav", "url": null, "hostname": null, "description": "Background: Since December 2019, severe acute respiratory syndrome coronavirus to developing severe acute respiratory disease originated from Wuhan, China, and further spread rapidly all over the world except very few counties. On 30th January 2020, The WHO confirmed the epidemic as a community health crisis all over world. No drug was approved for treatment but some conventional and traditional medicinal plants are being used against COVID-19 infections. Objective: The present review is to illustrate current updates on conventional and traditional herbal medicine used for deterrent and treatment of SARS-CoV-2 infection. Methods: Search engines like Scopus, Pubmed, and World Health Organization (WHO) literature on current advances about novel coronavirus (COVID-19) were reviewed. Discussion and Conclusion: Current research data indicated that the outbreaks caused by SARS MERS and COVID-19 have produced substantial community health problems. Currently, there are no vaccines for prevention or specific treatments however it can be managed by using oxygen therapy, convalescent plasma therapy, antimalarial drugs, and broad-spectrum antiviral drugs. Many traditional herbal and Chinese medicines may be useful.", "sitename": "Journal of Natural Remedies", "date": "2021-01-13", "cleaned_text": "Conventional Therapeutic Drugs and Traditional Herbal Medicine in Prevention and Treatment of Novel Corona Virus (COVID-19): An Update [Jump To References Section](#postbottom) DOI: [https://doi.org/10.18311/jnr/2020/25720](https://doi.org/10.18311/jnr/2020/25720) Keywords:Diagnosis, Conventional Drugs, Traditional Herbal Medicine, COVID-19 AbstractBackground: Since December 2019, severe acute respiratory syndrome coronavirus to developing severe acute respiratory disease originated from Wuhan, China, and further spread rapidly all over the world except very few counties. On 30th January 2020, The WHO confirmed the epidemic as a community health crisis all over world. No drug was approved for treatment but some conventional and traditional medicinal plants are being used against COVID-19 infections. Objective: The present review is to illustrate current updates on conventional and traditional herbal medicine used for deterrent and treatment of SARS-CoV-2 infection. Methods: Search engines like Scopus, Pubmed, and World Health Organization (WHO) literature on current advances about novel coronavirus (COVID-19) were reviewed. Discussion and Conclusion: Current research data indicated that the outbreaks caused by SARS MERS and COVID-19 have produced substantial community health problems. Currently, there are no vaccines for prevention or specific treatments however it can be managed by using oxygen therapy, convalescent plasma therapy, antimalarial drugs, and broad-spectrum antiviral drugs. Many traditional herbal and Chinese medicines may be useful. Downloads Metrics References Gralinski LE, Menachery Medicine. 2020. [https://doi.org/10.1016/S22132600(20)30056-4](https://doi.org/10.1016/S22132600(20)30056-4) World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020; 2020. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; S0140-6736(0120):30183-5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv; 2020. [https://doi.org/10.1101/2020.02.06.20020974](https://doi.org/10.1101/2020.02.06.20020974) World Health Organization COVID-19 Corona virus Pandemic [Internet]. 2019. Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; S0140-6736(0120):30154-9. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; https:// Peersen OB, Denison MR. Homology-based identification of a mutation in the coronavirus RNAdependent RNA polymerase that confers resistance to multiple Virology. 2016; 90(16):7415-28. [https://doi.org/10.1128/JVI.00080-16](https://doi.org/10.1128/JVI.00080-16). PMid:27279608 reverse transcription-polymerase chain reaction assay Hardie A, Claas EC et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. JCM.00636-10. PMid:20554810 PMCid:PMC2916580 Jan H, Faisal S, Khan A, Khan S, Usman H, Liaqat R, et al. COVID-19: Review of epidemiology and potential treatments against 2019 Discoveries (Craiova). 2020; Structure of SARS coronavirus spike Science. 2005; 309 (5742):1864-8. [https://doi.org/10.1126/science.1116480](https://doi.org/10.1126/science.1116480). PMid:16166518 Wang, Wu Q, Xu W, Qiao B, Wang J, Zheng H, et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv of novel coronavirus (2019-nCoV) | CDC [Internet]. (cited 2020 Mar 18). Available from: www.cdc.gov. 2020. WHO Coronavirus Disease 2019 (COVID-19). WHO. Health topic/Corona virus; 2020. Singhal T. A review of coronavirus disease-2019 PMid:32166607 PMCid:PMC7090728 JM, Meyer RF, et al. Real-time reverse transcriptionpolymerase chain Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal disease 2019 (COVID-19) pandemic: International variation of Personal Protective Equipment (PPE) and Infection Prevention and Control (IPC) guidelines. Anesthesia & Analgesia. 2020; 10(1213):1-6. Whittle JS, Pavlov I, Sacchetti AD, Atwood C, Rosenberg MS. Respiratory support for adult patients with COVID19. JACEP plasma therapy for corona virus disease 2019: A long way to go but worth trying. Journal of Korean Medical Science. 2020 Apr as a promising strategy for the treatment of emerging viral diseases. Pharmacology Research & Perspectives. 2017; 5(1):e00293 [https://doi.org/10.1002/](https://doi.org/10.1002/) prp2.293. PMid:28596841 PMCid:PMC5461643 Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus Cell Research. Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with Singapore. JAMA. IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial Thorax. 2004; 59(3):252-6. [https://doi.org/10.1136/thorax.2003.012658](https://doi.org/10.1136/thorax.2003.012658). PMid:14985565 PMCid:PMC1746980 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. Journal of Medical Virology. 2020; 92(5):479-90. [https://doi.org/10.1002/jmv.25707](https://doi.org/10.1002/jmv.25707). PMid:32052466 PMCid:PMC7166986 Lee N, Ng EK, Wu A, Chiu RW, et al. Effects of early corticosteroid treatment on plasma SARSassociated Coronavirus RNA concentrations in adult patients. Journal of Clinical Virology. 2004; 31(4):304-9. [https://doi.org/10.1016/j.jcv.2004.07.006](https://doi.org/10.1016/j.jcv.2004.07.006). PMid:15494274 PMCid:PMC7108318 Ferrey AJ, Choi G, Hanna RM, Chang Y, Tantisattamo E, Ivaturi K, et al. A case of novel coronavirus disease 19 in a chronic hemodialysis patient presenting with gastroenteritis and developing severe pulmonary disease. American Journal of Nephrology. 2020; 28:1-6. [https://doi.org/10.1159/000507417](https://doi.org/10.1159/000507417). PMid:32222713 PMCid:PMC7179539 Hu W, Fu W, Wei X, Yang Y, Lu C, Liu Z. A network pharmacology study on the active ingredients and potential targets of Tripterygium wilfordii Hook for treatment of rheumatoid arthritis. Medicine. 2019; 5276865:1-16. https:// doi.org/10.1155/2019/5276865. PMid:31118961 PMCid:PMC6500618 Zhang W, Huai Y, Miao Z, Qian A, Wang Y. Systems pharmacology for investigation of the mechanisms of action of traditional Chinese medicine in drug discovery. Frontiers in Pharmacology. 2019; 10(9743):1-6. https:// doi.org/10.3389/fphar.2019.00743. PMid:31379563 PMCid:PMC6657703 Yang Y, Islam MS, Wang J, Li Y, Xin C. Traditional Chinese medicine in the treatment of patients infected with 2019new coronavirus (SARS-CoV-2): A review and perspective. International Journal of Biological Sciences. 2020; 16:1708- 17. [https://doi.org/10.7150/ijbs.45538](https://doi.org/10.7150/ijbs.45538). PMid:32226288 PMCid:PMC7098036 Zhang H, Chen Q, Zhou W, Gao S, Lin H, Ye S, et al. Chinese medicine injection shuanghuanglian for treatment of acute upper respiratory tract infection: A systematic review of randomized controlled trials. EvidenceBased Complementary and Alternative Medicine. 2013; 2013:987326. [https://doi.org/10.1155/2013/987326](https://doi.org/10.1155/2013/987326). PMid:23606893 PMCid:PMC3625553 Ma Q, Yu Q, Xing X, Liu S, Shi C, Luo J, San Wu. Huangqin decoction, a Chinese herbal formula, inhibits influenza a/ PR/8/34 (H1N1) virus infection in 2018; 10(3):117. [https://doi.org/10.3390/v10030117](https://doi.org/10.3390/v10030117). PMid:29522425 PMCid:PMC5869510 Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription Lianhua qingwen capsule exerts anti influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complementary & Alternative Medicine. 2107; 17:130. [https://doi.org/10.1186/](https://doi.org/10.1186/) s12906-017-1585-7. PMid:28235408 PMCid:PMC5324200 Du H, Zhou H, Wan H, Yang J, Lu Y, He Y, Wan H. Antiviral effects and mechanisms of Yinhuapinggan granule against H1N1 influenza 2018; 26(6):1455-67. [https://doi.org/10.1007/s10787-018-0457-1](https://doi.org/10.1007/s10787-018-0457-1). PMid:29502306 Liu D, Liang B, Huang L, Fang Y, Zheng J, Wang G, et al. Clinical observation on the preventive effect of kangdu bufei decoction on acute severe respiratory syndrome. Chinese Journal of Integrated Traditional and Western Medicine. 2004, 24:685-8. Tong X, Li A, Zhang Z, Duan J, Chen X, Hua C, et al. TCM treatment of infectious atypical pneumonia--a report of 16 cases. Journal of Traditional Chinese Medicine. 2004; 24(4):266-9. Liu B, He L, Liang Z, Tong X, Hu J, Ni Q, et al. Effect of Chinese Herbal Medicine on adrenal glucocorticoids in SARS. China Journal of Chinese Materia Medica. 2005; 30(23):1874-7. Hai X. Clinical experience of SARS treatment in Guangdong province. Tianjin Journal of Traditional Chinese. 2003; 20(3):24-5. Jia J. Traditional Chinese Medicine integrated western medicine for SARS. Tianjin Journal of Traditional Chinese. 2003; 20(3):28-30. Liu LS, Lei N, Lin Q, Wang WL, Yan HW, Duan XH. The effects mechanism of Yinqiao powder on upper respiratory tract infection. International Journal of Biotechnology for Wellness Industries. 2015; 4:57-60. [https://doi.org/10.6000/1927-3037.2015.04.02.2](https://doi.org/10.6000/1927-3037.2015.04.02.2) Fu YJ, Yan YQ, Qin HQ, Wu S, Shi SS, Zheng X, et al. Effects of different principles of Traditional Chinese Medicine treatment on TLR7/NF-\u00ce\u00baB signaling pathway in influenza virus infected mice. Chinese Medical Journal. 2018; 13:42. [https://doi.org/10.1186/s13020-018-0199-4](https://doi.org/10.1186/s13020-018-0199-4). PMid:30151032 PMCid:PMC6102858 Lau JT, Leung PC, Wong EL, Fong C, Cheng KF, Zhang SC, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. Journal of Alternative and Complementary Medicine. 2005; 11:49-55. [https://doi.org/10.1089/acm.2005.11.49](https://doi.org/10.1089/acm.2005.11.49). PMid:15750363 Du CY, Zheng KY, Bi CW, Dong TT, Lin H, Tsim KW. Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti-viral proteins and inhibits neuraminidase activity. Phytotherapy Research. 2015; 29:656-61. [https://doi.org/10.1002/ptr.5290](https://doi.org/10.1002/ptr.5290). PMid:25586308 Gao J, Li J, Shao X, Jin Y, Lu XW, Ge JF, et al. Antiinflammatory and immunoregulatory effects of total glucosides Yupingfeng powder. Medical (Engl). 2009; 122:1636-41. Poon PM, Wong CK, Fung KP, Fong CY, Wong EL, Lau JT, et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study. American Journal of Chinese Medicine. 2006; 34:13-21. [https://doi.org/10.1142/S0192415X0600359X](https://doi.org/10.1142/S0192415X0600359X). PMid:16437735 Dong L, Xia JW, Gong Y, Chen Z, Yang H-H, Zhang J, et al. Effect of Lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease. Evidence-Based Complementary and Alternative Medicine. 2014; 2014:1- 11. [https://doi.org/10.1155/2014/637969](https://doi.org/10.1155/2014/637969). PMid:24971150 PMCid:PMC4058171 Gao Y, Fang L, Cai R, Zong C, Chen X, Lu J, et al. ShuangHuang-Lian exerts Yuan CJ, et al. A literature report on the treatment of SARS by stages with traditional Chinese medicine. J Emerg Chin Med Hunan. 2005: 53-5. Bao L, J M. Research progress of Da Yuan Yin on the treatment of infectious diseases. Emerg Tradit Chin Med. 2010; 2:263- 87. Cragg GM, Newman DJ. Natural products: a continuing source of novel drug Acta. 2013; 1830:3670-95. [https://doi.org/10.1016/j.bbagen.2013.02.008](https://doi.org/10.1016/j.bbagen.2013.02.008). PMid:23428572 PMCid:PMC3672862 Luo W, Su X, Gong S, Qin Y, Liu W, Li J, et al. Anti-SARS coronavirus 3C-like protease effects of 3. Fung KP, Leung PC, Tsui KW, Wan CC, Wong KB, Waye MY, et al. Immunomodulatory activities of the herbal formula Kwan Du Bu Fei Dang in healthy subjects: A randomised, double-blind, placebo-controlled study. Hong Kong Medical Journal. 2011; 17 Suppl 2:41-3. Lau KM, Lee KM, Koon CM, Cheung CS, Lau CP, Ho HM, et al. Immunomodulatory and anti-SARS HP, Li J, Qin YJ, Xu Q, et al. A study on anti-SARS-CoV 3CL protein of flavonoids Bulletin. Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Kim YM, Kim et al. Flavonoid-mediated inhibition of SARS coronavirus Letters. 2012; [https://doi.org/10.1007/s10529-011-0845-8](https://doi.org/10.1007/s10529-011-0845-8). PMid:22350287 PMCid:PMC7087583 Jo 35:145-51. [https://doi.org/10.1080/14756366.2019.1690480](https://doi.org/10.1080/14756366.2019.1690480) PMid:31724441 PMCid:PMC6882434 Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS CoV 3Clike protease inhibitors. Chemical Biology & Drug Design. 2019. [https://doi.org/10.1111/cbdd.13604](https://doi.org/10.1111/cbdd.13604). PMid:31436895 PMCid:PMC7162010 Yu MS, Lee J, Lee JM, Kim Y, Chin YW, Jee JG, et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101:10012-7. [https://doi.org/10.1073/pnas.0403596101](https://doi.org/10.1073/pnas.0403596101). PMid:15226499 PMCid:PMC454157 Downloads Published "}